Peptide Reference Database
Clinical reference database covering mechanisms, dosing protocols, combinations, and contraindications.
Want a personalised protocol?
Our AI generator builds a protocol tailored to your profile and goals.
8 peptides
Tesamorelin
Egrifta Β· TH9507
FDA-approved GHRH analogue specifically indicated for HIV-associated lipodystrophy.
Semaglutide
Ozempic Β· Wegovy
Long-acting GLP-1 receptor agonist with FDA approval for T2 diabetes and obesity.
Tirzepatide
Mounjaro Β· Zepbound
Dual GIP/GLP-1 receptor agonist (first in class) with superior weight loss outcomes (~22% body weight) compared to semaglutide in head-to-head trials.
Retatrutide
LY3437943 Β· Triple Agonist
First-in-class triple GIP/GLP-1/glucagon receptor agonist (Eli Lilly) in Phase 3 trials.
AOD-9604
Anti-Obesity Drug 9604 Β· hGH Fragment 176-191
Fragment of human GH (amino acids 176β191) that retains the lipolytic activity of GH without promoting growth or affecting blood sugar.
5-Amino-1MQ
5-amino-1-methylquinolinium Β· NNMT inhibitor
Small molecule NNMT inhibitor that reactivates dormant fat cells' metabolism.
MOTS-c
Mitochondrial Open Reading Frame of the 12S rRNA-c
Mitochondria-derived peptide that acts as a metabolic regulator, improving insulin sensitivity and exercise capacity.
ARA-290
Cibinetide Β· Helix B Surface Peptide
11-amino acid peptide derived from the helix B surface of erythropoietin (EPO) that retains EPO's tissue-protective properties without haematopoietic activity.
MaraPeptide Β· NAD+ revolution
Improve your energy, appearance and recovery the natural way in just a few weeks
Complete NAD+ protocol for free!